Alaunos Therapeutics Inc
$ 1.90
-0.26%
04 Aug - close price
- Market Cap 4,859,900 USD
- Current Price $ 1.90
- High / Low $ 1.96 / 1.85
- Stock P/E N/A
- Book Value 0.54
- EPS -2.12
- Next Earning Report 2026-08-13
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -1.29 %
- ROE -3.50 %
- 52 Week High 4.59
- 52 Week Low 1.67
About
Alaunos Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on discovering, acquiring, developing and commercializing a portfolio of immuno-oncology therapies to treat cancer patients. The company is headquartered in Houston, Texas.
Analyst Target Price
$1.75
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-14 | 2025-08-14 | 2025-05-15 | 2025-03-31 | 2024-11-14 | 2024-08-14 | 2024-04-02 | 2024-03-05 | 2023-11-14 | 2023-08-14 | 2023-05-10 | 2023-03-07 |
| Reported EPS | -0.55 | -0.63 | -0.67 | -0.4634 | -0.7038 | -0.7051 | -17.09 | -0.49 | -4.41 | -6 | -6 | -0.04 |
| Estimated EPS | 0 | None | None | None | None | None | -4.5 | -0.45 | -5.25 | -6.75 | -6.6 | -0.07 |
| Surprise | -0.55 | 0 | 0 | 0 | 0 | 0 | -12.59 | -0.04 | 0.84 | 0.75 | 0.6 | 0.03 |
| Surprise Percentage | None% | None% | None% | None% | None% | None% | -279.7778% | -8.8889% | 16% | 11.1111% | 9.0909% | 42.8571% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-13 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: TCRT
2026-08-06 08:40:00
This article provides the enterprise value to EBITDA forward for Alaunos Therapeutics, Inc. (NASDAQ: TCRT). It is a financial data point presented by TradingView, indicating a specific valuation metric for the biotechnology company. The content appears to be a financial data page rather than an analytical article.
2026-08-01 20:40:49
This article provides a brief financial snippet for Alaunos Therapeutics, Inc. (NASDAQ: TCRT), focusing on its enterprise value to EBIT forward metric. The content itself is very minimal, essentially a placeholder or header indicating where detailed financial information would typically be presented on the TradingView platform. It does not offer any specific financial figures or analysis within the provided text.
2026-07-31 09:41:01
This article from TradingKey provides a revenue breakdown for Alaunos Therapeutics Inc (TCRT). It notes that relevant data regarding business segments, regional revenue, and profit contribution have not yet been disclosed by the company. The page also displays the current stock price and market capitalization for TCRT.
2026-07-30 09:39:34
Alaunos Therapeutics Inc (TCRT) has a current financial score of 7.34, ranking 128th out of 384 in the Biotechnology & Medical Research industry, indicating robust financial status but low operating efficiency. Its latest quarterly revenue saw a 100.00% year-over-year decrease, and net profit decreased by 6.24% year-over-year. The financial analysis highlights areas like Quality of Earnings, Operational Efficiency, Growth Potential, and Shareholder Returns, noting that relevant data for several categories have not yet been disclosed by the company.
2026-07-27 20:18:06
Robert W. Postma, a director at Alaunos Therapeutics, Inc. (TCRT), received 8,463 shares of common stock on July 23, 2026, valued at $1.92 per share, as compensation for board fees. This transaction increased his direct holdings to 58,609 shares, with additional indirect holdings through his spouse's IRA and WaterMill Asset Management Corp. The filing indicates a neutral impact and sentiment on the company's stock.
2026-07-27 20:18:06
Alaunos Therapeutics director Michael Allen Jerman received a grant of 8,138 shares of common stock on July 23, 2026, valued at $1.92 per share, in lieu of board fees. This transaction increased his direct holdings to 23,759 shares. The Form 4 filing details the acquisition and confirms that these shares were compensation for his service on the board.
